10-Q: Natures Sunshine Reports Strong Q3 Growth, New CEO Appointed

Natures Sunshine Products, Inc. announced significant increases in net sales and net income for the third quarter and first nine months of 2025, alongside the appointment of Kenneth G. Romanzi as its new Chief Executive Officer.

Summary

• Consolidated net sales for the three months ended September 30, 2025, increased by 12.0% to $128.3 million, or 10.5% in local currencies, compared to $114.6 million in the prior year.
• Net sales for the nine months ended September 30, 2025, rose by 6.0% to $356.3 million, or 5.8% in local currencies, from $336.2 million in the same period of 2024.
• Gross profit for the third quarter increased by 15.0% to $94.0 million, with gross margin improving to 73.3% from 71.3% in the prior year.
• Operating income for the third quarter surged by 69.9% to $9.0 million, representing 7.0% of net sales, up from $5.3 million (4.6% of net sales) in the prior year.
• Net income attributable to common shareholders for the third quarter increased by 22.7% to $5.3 million, resulting in diluted EPS of $0.30, compared to $4.3 million and $0.23 diluted EPS in 2024.
• Net income attributable to common shareholders for the nine months increased by 92.3% to $15.4 million, with diluted EPS of $0.83, compared to $8.0 million and $0.42 diluted EPS in 2024.
• Asia segment net sales grew by 17.1% (14.9% local currency) in Q3 2025, driven by strong performance in Japan (+33.2% USD, +31.5% local currency) and China (+35.7% USD, +35.8% local currency).
• Europe segment net sales increased by 12.7% (10.0% local currency) in Q3 2025 due to improved customer acquisition and engagement.
• North America net sales increased by 7.7% (7.8% local currency) in Q3 2025, with U.S. sales up 8.3% due to digital channel customer acquisition and core business stabilization.
• Latin America and Other net sales decreased by 13.1% (13.3% local currency) in Q3 2025.
• Cash and cash equivalents increased to $95.6 million as of September 30, 2025, from $84.7 million at December 31, 2024.
• Operating activities provided $25.4 million in cash for the nine months ended September 30, 2025, up from $13.1 million in the prior year.
• The company repurchased 1,129,000 shares of common stock for $14.4 million during the nine months ended September 30, 2025, with $19.3 million remaining under the repurchase program.
• The company entered into agreements to purchase Fosun Industrial's interests in two China joint ventures for a total of $7.0 million, subject to regulatory approvals.
• An internal investigation into past compliance with U.S. trade controls resulted in final voluntary self-disclosures to BIS and OFAC on September 5, 2025; potential violations represented less than one percent of net revenue in the last three fiscal years, and any fines are not expected to be material.

Sentiment

Score: 8

Explanation: The company demonstrated strong financial performance with significant increases in net sales, gross profit, operating income, and net income for both the quarter and nine-month periods. Strategic moves like consolidating China joint ventures and continued share repurchases are positive. While some segments faced declines and geopolitical risks persist, the overall financial health and operational improvements are very positive.

Positives

• Net sales increased significantly by 12.0% in Q3 2025 and 6.0% for the nine months, demonstrating strong top-line growth.
• Gross profit margin improved to 73.3% in Q3 2025 from 71.3% in Q3 2024, driven by cost savings, market mix, and favorable foreign exchange.
• Operating income saw substantial growth, increasing by 69.9% in Q3 2025 and 24.9% for the nine months, indicating improved operational efficiency.
• Net income attributable to common shareholders more than doubled for the nine-month period, rising by 92.3% to $15.4 million.
• Diluted EPS increased to $0.30 in Q3 2025 and $0.83 for the nine months, reflecting enhanced profitability per share.
• Strong performance in key international markets, with Asia net sales up 17.1% and Europe net sales up 12.7% in Q3 2025.
• Japan market showed exceptional growth with net sales increasing by 33.2% in Q3 2025, attributed to strong field fundamentals and customer acquisition.
• China market experienced robust growth with net sales up 35.7% in Q3 2025, driven by higher total orders and improved consultant engagement.
• Cash and cash equivalents increased to $95.6 million, and net cash provided by operating activities significantly improved to $25.4 million for the nine-month period.
• The company continues to return value to shareholders through its share repurchase program, with $19.3 million remaining for future repurchases.

Negatives

• Latin America and Other segment experienced a decrease in net sales of 13.1% in Q3 2025 and 7.6% for the nine months.
• Taiwan market saw a decrease in local currency net sales of 4.8% in Q3 2025, primarily due to a reduction in total orders and average order value.
• Foreign exchange gains, net, decreased significantly in Q3 2025 to $0.7 million from $2.7 million in Q3 2024, although they increased for the nine-month period.
• Selling, general and administrative expenses increased by $4.8 million in Q3 2025 and $9.7 million for the nine months, primarily due to compensation costs, digital marketing, and consultant events.

Risks

• Extensive government regulations to which products, business practices, and manufacturing activities are subject, including trade restrictions and export controls.
• Difficulty or increased cost of importing products into foreign markets or registering products for sale in foreign markets.
• Legal challenges to the direct selling program or to the classification of independent consultants.
• Laws and regulations regarding direct selling may prohibit or restrict the ability to sell products in some markets or require changes to the business model.
• Liabilities and obligations arising from improper activity by independent consultants.
• Product liability claims.
• Impact of anti-bribery laws, including the U.S. Foreign Corrupt Practices Act.
• Ability to attract and retain independent consultants.
• Loss of one or more key independent consultants who have a significant sales network.
• Effect of fluctuating foreign exchange rates.
• Failure of independent consultants to comply with advertising laws.
• Changes to independent consultants' compensation plans.
• Geopolitical issues and conflicts, including changes to U.S. trade policy resulting in new or additional tariffs.
• Negative consequences resulting from difficult economic conditions, including liquidity availability or customer willingness to purchase products.
• Risks associated with the manufacturing of products.
• Supply chain disruptions, manufacturing interruptions or delays, or failure to accurately forecast customer demand.
• Failure to timely and effectively obtain shipments of products from suppliers and contract manufacturers and deliver products to independent consultants and customers.
• World-wide slowdowns and delays related to supply chain, ingredient shortages, and logistical challenges.
• Uncertainties relating to the application of transfer pricing, duties, value-added taxes, and other tax regulations, and changes thereto.
• Changes in tax laws, treaties or regulations, or their interpretation.
• Failure to maintain an effective system of internal controls over financial reporting.
• Cybersecurity threats and exposure to data loss.
• Storage, processing, and use of data, some of which contain personal information, are subject to complex and evolving privacy and data protection laws and regulations.
• Reliance on information technology infrastructure.
• Sufficiency of trademarks and other intellectual property rights.
• Unfavorable outcome of the internal investigation regarding past compliance with U.S. trade controls, potentially leading to fines or penalties.
• Material adverse effect on business and results of operations due to uncertainty and changes in U.S. trade policies, including tariffs and retaliatory measures.

Future Outlook

The company expects foreign markets with functional currencies other than the U.S. Dollar to continue representing a substantial portion of overall sales and operating expenses, making results susceptible to foreign currency fluctuations. The conflict in Eastern Europe is expected to continue impacting business at a reduced level for the foreseeable future. While higher tariffs have begun affecting costs in 2025, the full-year impact is not expected to be material. The company believes that cash generated from operations, along with available cash and cash equivalents, will be sufficient to fund normal operating needs, including capital expenditures, on both a shortand long-term basis.

Management Comments

• Experienced an increase in consolidated net sales of 12.0 percent (10.5 percent in local currencies) in the third quarter of 2025 compared to the same period in 2024.
• The decrease in cost of sales percentage is primarily due to cost savings initiatives, market mix, and favorable foreign exchange.
• The increase in selling, general and administrative expenses was primarily related to the timing of compensation costs, incremental investment in digital marketing, and consultant events, as well as other non-recurring expenses.
• Consultants in Eastern Europe continue to operate their independent businesses, albeit at a reduced level than prior to the start of the conflict, and this is expected to continue to impact the business for the foreseeable future.
• While the amount of any fines or penalties from the trade controls investigation is not expected to be material to financial condition and results of operation, the outcome and resolution time are currently unpredictable.
• The increase in net sales in Japan was primarily the result of strong field fundamentals and timing of event qualifications that drove greater customer acquisition and an increase in total orders and average order value.
• The increase in net sales in China was primarily the result of higher total orders driven by improved consultant engagement.
• The increase in U.S. net sales was primarily due to improved customer acquisition through digital channels as well as stabilization of the core business.
• Operating cash flows increased primarily due to improved net income and the timing of payments for accrued liabilities, accrued volume incentives and service fees, and deferred revenue, partially offset by an increase in inventories and reduction in account payables.
• Believe that cash generated from operations, along with available cash and cash equivalents, will be sufficient to fund normal operating needs, including capital expenditures, on both a shortand long-term basis.

Industry Context

The company operates in the natural health and wellness industry, primarily through a direct selling model. Its performance reflects a strong rebound in key Asian and European markets, indicating resilience and effective engagement strategies within its consultant network. The growth in digital marketing and consultant events suggests an adaptation to modern sales and engagement tactics, which is a broader trend in the direct selling and wellness sectors. The acquisition of joint venture interests in China indicates a strategic move to consolidate control in a significant market, aligning with trends of companies seeking greater operational autonomy in key international regions. The ongoing geopolitical issues in Eastern Europe and global tariff uncertainties highlight the persistent external challenges faced by international businesses in this sector.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• Accrued liabilities of $0.7 million as of September 30, 2025, related to the estimated outcome of various legal proceedings and disputes in the United States and foreign jurisdictions.
• Potential future payments related to these matters could range from $0 to approximately $2.9 million.
• Internal investigation regarding past compliance with U.S. trade controls, with final voluntary self-disclosures filed with BIS and OFAC on September 5, 2025. Potential violations represented less than one percent of net revenue in the last three fiscal years, and any fines or penalties are not expected to be material.

Related Party Transactions

• On June 27, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma), through one of its affiliates, sold 2,854,607 shares of the Company's common stock, resulting in Fosun Pharma ceasing to own at least 5% of the outstanding shares.
• On June 30, 2025, the Company entered into share purchase agreements with Fosun Industrial Co., Ltd. (an affiliate of Fosun Pharma) to purchase Fosun Industrial's interest in Natures Sunshine Hong Kong Limited for $3.9 million and Shanghai Natures Sunshine Health Products Co., Ltd. for $3.1 million. These purchases are subject to customary closing conditions and regulatory submissions.

Stakeholder Impact

• Shareholders benefit from increased net income, diluted EPS, and the ongoing share repurchase program, which enhances shareholder value.
• Employees and independent consultants are impacted by increased selling, general and administrative expenses, which include compensation costs, digital marketing, and consultant events, suggesting continued investment in the sales force and operational support.
• Customers in Asia, Europe, and North America are experiencing improved customer acquisition and engagement, indicating successful product and marketing strategies.
• The consolidation of China joint ventures is expected to give the company sole ownership, potentially streamlining operations and strategic control in a key market.
• The ongoing trade controls investigation and potential tariffs introduce uncertainty for suppliers and could affect the cost and availability of raw materials and finished goods.

Next Steps

• Complete the purchase of Fosun Industrial's interests in Natures Sunshine Hong Kong Limited and Shanghai Natures Sunshine Health Products Co., Ltd., subject to customary closing conditions and regulatory approvals in the PRC.
• Continue monitoring the social, political, regulatory, and economic environment in Ukraine and Russia and consider further actions as appropriate.
• Resolve the internal investigation regarding past compliance with U.S. trade controls with BIS and OFAC.
• Kenneth G. Romanzi will commence employment as Chief Executive Officer on October 29, 2025.
• Kenneth G. Romanzi will be granted RSUs with a grant date fair value of no less than $1,500,000 during March 2026.

Key Dates

Recommendation

Natures Sunshine Products, Inc. delivered exceptionally strong financial results for Q3 and the first nine months of 2025, significantly outperforming the prior year across key metrics including net sales, gross profit, operating income, and net income. The substantial increase in diluted EPS, coupled with robust cash flow from operations, demonstrates improved profitability and financial health. Strategic moves such as consolidating control over China joint ventures and an active share repurchase program further enhance shareholder value and operational efficiency. While some regional weaknesses and geopolitical risks exist, the overall growth trajectory, particularly in key international markets like Japan and China, and the appointment of a new CEO, suggest a positive outlook for continued performance. The company's ability to expand margins despite increased SG&A expenses indicates effective cost management and strategic investments. These factors collectively point to a strong investment opportunity.

Keywords

Nutritional Supplements, Direct Selling, Health and Wellness, Multi-level Marketing, SEC Filing, Quarterly Report, Financial Results, Global Operations, Share Repurchase, Corporate Governance, Trade Controls, China Market, Asia Pacific, Europe Market, North America Market, Herbal Products, Personal Care